13,684 Shares of Danaher Corporation $DHR Purchased by Retirement Planning Co of New England Inc.

Retirement Planning Co of New England Inc. acquired a new stake in shares of Danaher Corporation (NYSE:DHR) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 13,684 shares of the conglomerate’s stock, valued at approximately $3,032,000. Danaher makes up about 1.1% of Retirement Planning Co of New England Inc.’s holdings, making the stock its 19th biggest position.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. BlackRock Inc. purchased a new position in shares of Danaher in the second quarter worth approximately $10,492,520,000. Jupiter Topco LLC acquired a new stake in shares of Danaher during the second quarter valued at approximately $1,456,317,000. Generation Investment Management LLP purchased a new stake in shares of Danaher in the 2nd quarter valued at approximately $1,287,949,000. Bank of America Corp DE purchased a new stake in shares of Danaher in the 2nd quarter valued at approximately $993,846,000. Finally, Legal & General Group Plc purchased a new stake in shares of Danaher in the 2nd quarter valued at approximately $801,056,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Up 3.0%

NYSE:DHR opened at $231.52 on Friday. The stock has a market cap of $162.76 billion, a PE ratio of 41.12, a price-to-earnings-growth ratio of 2.82 and a beta of 0.76. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The stock’s 50-day moving average is $213.55 and its two-hundred day moving average is $195.74.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm’s revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.77 earnings per share. As a group, equities research analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s payout ratio is presently 28.42%.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, October 10th. Royal Bank Of Canada boosted their target price on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research note on Monday, October 5th. Wells Fargo & Company cut their target price on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 22nd. The Goldman Sachs Group increased their target price on Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a report on Monday, September 21st. Finally, Evercore reaffirmed an “outperform” rating and issued a $230.00 target price on shares of Danaher in a research report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average price target of $235.41.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.